Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TORONTO, 20 avr. 2026 (GLOBE NEWSWIRE) -- Le Fonds humanitaire des Métallos (FHM) verse 15 950 $ en aide d’urgence à Cuba pour l'achat de fournitures et d'équipements médicaux, en partenariat avec...
-
The Steelworkers Humanity Fund matched monies raised from the basketball tournament, resulting in $15,950 in relief funds for Cuba.
-
Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Single Use Bioprocessing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Product, Scale of Operation and Key...
-
Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Drug-Eluting Stents Market Report by Coating, Drug, Stent Platform, Generation, Application, End User, and Region ?2026-2034?" has been added to ...
-
Divests Older, Less Fuel-Efficient Vessels and Agrees to Acquire High Specification Scrubber-Fitted Capesize Vessel Increased Exposure to Premium Earning Capesize Vessels Further Enhances Earnings...
-
Nayax will showcase its end-to-end unattended retail payments platform at NAMA Show 2026, featuring smart tools, embedded finance & loyalty solutions.
-
Howard’s nationwide reach across healthcare and public sector markets expands Nanox’s U.S. channel partner network to additional customer segments PETAH TIKVA, Israel, April 20, 2026 -- Nano-X...
-
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
Updated AACR poster data show continued survival follow-up in heavily pre‑treated patients following a single intratumoral UNO injection Received US patent allowance covering proprietary gas...
-
ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe Première étude comparative de phase 4, randomisée, en...
-
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the...